The global Radioimmunotherapy market size was valued at USD 1073 million in 2022 and is forecast to a readjusted size of USD 3159.2 million by 2029 with a CAGR of 16.7% during review period.
Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non-Hodgkin Lymphoma.
Report includes an overview of the development of the Radioimmunotherapy industry chain, the market status of Solid Tumor (Beta-emitting, Targeted Alpha Therapy), Non-Hodgkin Lymphoma (Beta-emitting, Targeted Alpha Therapy), and key enterprises in developed and developing market, and analyzed the cutting-edge technology, patent, hot applications and market trends of Radioimmunotherapy.
Regionally, the report analyzes the Radioimmunotherapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Radioimmunotherapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Radioimmunotherapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Radioimmunotherapy industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Beta-emitting, Targeted Alpha Therapy).
Industry Analysis: Report analyze the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Radioimmunotherapy market.
Regional Analysis: The report involves examining the Radioimmunotherapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behavior to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Radioimmunotherapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Radioimmunotherapy:
Company Analysis: Report covers individual Radioimmunotherapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behavior, preferences, and attitudes towards Radioimmunotherapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumor, Non-Hodgkin Lymphoma).
Technology Analysis: Report covers specific technologies relevant to Radioimmunotherapy. It assesses the current state, advancements, and potential future developments in Radioimmunotherapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Radioimmunotherapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Beta-emitting
Targeted Alpha Therapy
Solid Tumor
Non-Hodgkin Lymphoma
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Radioimmunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Radioimmunotherapy, with revenue, gross margin and global market share of Radioimmunotherapy from 2018 to 2023.
Chapter 3, the Radioimmunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Radioimmunotherapy market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Radioimmunotherapy.
Chapter 13, to describe Radioimmunotherapy research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Radioimmunotherapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Radioimmunotherapy by Type
1.3.1 Overview: Global Radioimmunotherapy Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Radioimmunotherapy Consumption Value Market Share by Type in 2022
1.3.3 Beta-emitting
1.3.4 Targeted Alpha Therapy
1.4 Global Radioimmunotherapy Market by Application
1.4.1 Overview: Global Radioimmunotherapy Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Solid Tumor
1.4.3 Non Hodgkin Lymphoma
1.5 Global Radioimmunotherapy Market Size & Forecast
1.6 Global Radioimmunotherapy Market Size and Forecast by Region
1.6.1 Global Radioimmunotherapy Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Radioimmunotherapy Market Size by Region, (2018-2029)
1.6.3 North America Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.4 Europe Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.6 South America Radioimmunotherapy Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Radioimmunotherapy Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Bayer
2.1.1 Bayer Details
2.1.2 Bayer Major Business
2.1.3 Bayer Radioimmunotherapy Product and Solutions
2.1.4 Bayer Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Bayer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Radioimmunotherapy Product and Solutions
2.2.4 Novartis Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Lantheus
2.3.1 Lantheus Details
2.3.2 Lantheus Major Business
2.3.3 Lantheus Radioimmunotherapy Product and Solutions
2.3.4 Lantheus Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Lantheus Recent Developments and Future Plans
2.4 Aurobindo Pharma
2.4.1 Aurobindo Pharma Details
2.4.2 Aurobindo Pharma Major Business
2.4.3 Aurobindo Pharma Radioimmunotherapy Product and Solutions
2.4.4 Aurobindo Pharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Aurobindo Pharma Recent Developments and Future Plans
2.5 Mundipharma
2.5.1 Mundipharma Details
2.5.2 Mundipharma Major Business
2.5.3 Mundipharma Radioimmunotherapy Product and Solutions
2.5.4 Mundipharma Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Mundipharma Recent Developments and Future Plans
2.6 China Isotope & Radiation
2.6.1 China Isotope & Radiation Details
2.6.2 China Isotope & Radiation Major Business
2.6.3 China Isotope & Radiation Radioimmunotherapy Product and Solutions
2.6.4 China Isotope & Radiation Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 China Isotope & Radiation Recent Developments and Future Plans
2.7 Curium Pharmaceuticals
2.7.1 Curium Pharmaceuticals Details
2.7.2 Curium Pharmaceuticals Major Business
2.7.3 Curium Pharmaceuticals Radioimmunotherapy Product and Solutions
2.7.4 Curium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Curium Pharmaceuticals Recent Developments and Future Plans
2.8 Gilead Sciences
2.8.1 Gilead Sciences Details
2.8.2 Gilead Sciences Major Business
2.8.3 Gilead Sciences Radioimmunotherapy Product and Solutions
2.8.4 Gilead Sciences Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Gilead Sciences Recent Developments and Future Plans
2.9 Clarity Pharmaceuticals
2.9.1 Clarity Pharmaceuticals Details
2.9.2 Clarity Pharmaceuticals Major Business
2.9.3 Clarity Pharmaceuticals Radioimmunotherapy Product and Solutions
2.9.4 Clarity Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Clarity Pharmaceuticals Recent Developments and Future Plans
2.10 Curasight
2.10.1 Curasight Details
2.10.2 Curasight Major Business
2.10.3 Curasight Radioimmunotherapy Product and Solutions
2.10.4 Curasight Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Curasight Recent Developments and Future Plans
2.11 Nordic Nanovector
2.11.1 Nordic Nanovector Details
2.11.2 Nordic Nanovector Major Business
2.11.3 Nordic Nanovector Radioimmunotherapy Product and Solutions
2.11.4 Nordic Nanovector Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Nordic Nanovector Recent Developments and Future Plans
2.12 Philogen
2.12.1 Philogen Details
2.12.2 Philogen Major Business
2.12.3 Philogen Radioimmunotherapy Product and Solutions
2.12.4 Philogen Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Philogen Recent Developments and Future Plans
2.13 RadioMedix
2.13.1 RadioMedix Details
2.13.2 RadioMedix Major Business
2.13.3 RadioMedix Radioimmunotherapy Product and Solutions
2.13.4 RadioMedix Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 RadioMedix Recent Developments and Future Plans
2.14 Telix Pharmaceuticals
2.14.1 Telix Pharmaceuticals Details
2.14.2 Telix Pharmaceuticals Major Business
2.14.3 Telix Pharmaceuticals Radioimmunotherapy Product and Solutions
2.14.4 Telix Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Telix Pharmaceuticals Recent Developments and Future Plans
2.15 Orano Med
2.15.1 Orano Med Details
2.15.2 Orano Med Major Business
2.15.3 Orano Med Radioimmunotherapy Product and Solutions
2.15.4 Orano Med Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.15.5 Orano Med Recent Developments and Future Plans
2.16 Actinium Pharmaceuticals
2.16.1 Actinium Pharmaceuticals Details
2.16.2 Actinium Pharmaceuticals Major Business
2.16.3 Actinium Pharmaceuticals Radioimmunotherapy Product and Solutions
2.16.4 Actinium Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.16.5 Actinium Pharmaceuticals Recent Developments and Future Plans
2.17 Y-mAbs Therapeutics
2.17.1 Y-mAbs Therapeutics Details
2.17.2 Y-mAbs Therapeutics Major Business
2.17.3 Y-mAbs Therapeutics Radioimmunotherapy Product and Solutions
2.17.4 Y-mAbs Therapeutics Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.17.5 Y-mAbs Therapeutics Recent Developments and Future Plans
2.18 Fusion Pharmaceuticals
2.18.1 Fusion Pharmaceuticals Details
2.18.2 Fusion Pharmaceuticals Major Business
2.18.3 Fusion Pharmaceuticals Radioimmunotherapy Product and Solutions
2.18.4 Fusion Pharmaceuticals Radioimmunotherapy Revenue, Gross Margin and Market Share (2018-2023)
2.18.5 Fusion Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Radioimmunotherapy Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Radioimmunotherapy by Company Revenue
3.2.2 Top 3 Radioimmunotherapy Players Market Share in 2022
3.2.3 Top 6 Radioimmunotherapy Players Market Share in 2022
3.3 Radioimmunotherapy Market: Overall Company Footprint Analysis
3.3.1 Radioimmunotherapy Market: Region Footprint
3.3.2 Radioimmunotherapy Market: Company Product Type Footprint
3.3.3 Radioimmunotherapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Radioimmunotherapy Consumption Value and Market Share by Type (2018-2023)
4.2 Global Radioimmunotherapy Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Radioimmunotherapy Consumption Value Market Share by Application (2018-2023)
5.2 Global Radioimmunotherapy Market Forecast by Application (2024-2029)
6 North America
6.1 North America Radioimmunotherapy Consumption Value by Type (2018-2029)
6.2 North America Radioimmunotherapy Consumption Value by Application (2018-2029)
6.3 North America Radioimmunotherapy Market Size by Country
6.3.1 North America Radioimmunotherapy Consumption Value by Country (2018-2029)
6.3.2 United States Radioimmunotherapy Market Size and Forecast (2018-2029)
6.3.3 Canada Radioimmunotherapy Market Size and Forecast (2018-2029)
6.3.4 Mexico Radioimmunotherapy Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Radioimmunotherapy Consumption Value by Type (2018-2029)
7.2 Europe Radioimmunotherapy Consumption Value by Application (2018-2029)
7.3 Europe Radioimmunotherapy Market Size by Country
7.3.1 Europe Radioimmunotherapy Consumption Value by Country (2018-2029)
7.3.2 Germany Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.3 France Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.5 Russia Radioimmunotherapy Market Size and Forecast (2018-2029)
7.3.6 Italy Radioimmunotherapy Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Radioimmunotherapy Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Radioimmunotherapy Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Radioimmunotherapy Market Size by Region
8.3.1 Asia-Pacific Radioimmunotherapy Consumption Value by Region (2018-2029)
8.3.2 China Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.3 Japan Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.4 South Korea Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.5 India Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Radioimmunotherapy Market Size and Forecast (2018-2029)
8.3.7 Australia Radioimmunotherapy Market Size and Forecast (2018-2029)
9 South America
9.1 South America Radioimmunotherapy Consumption Value by Type (2018-2029)
9.2 South America Radioimmunotherapy Consumption Value by Application (2018-2029)
9.3 South America Radioimmunotherapy Market Size by Country
9.3.1 South America Radioimmunotherapy Consumption Value by Country (2018-2029)
9.3.2 Brazil Radioimmunotherapy Market Size and Forecast (2018-2029)
9.3.3 Argentina Radioimmunotherapy Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Radioimmunotherapy Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Radioimmunotherapy Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Radioimmunotherapy Market Size by Country
10.3.1 Middle East & Africa Radioimmunotherapy Consumption Value by Country (2018-2029)
10.3.2 Turkey Radioimmunotherapy Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Radioimmunotherapy Market Size and Forecast (2018-2029)
10.3.4 UAE Radioimmunotherapy Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Radioimmunotherapy Market Drivers
11.2 Radioimmunotherapy Market Restraints
11.3 Radioimmunotherapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Radioimmunotherapy Industry Chain
12.2 Radioimmunotherapy Upstream Analysis
12.3 Radioimmunotherapy Midstream Analysis
12.4 Radioimmunotherapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Radioimmunotherapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Radioimmunotherapy Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Radioimmunotherapy Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Radioimmunotherapy Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Bayer Company Information, Head Office, and Major Competitors
Table 6. Bayer Major Business
Table 7. Bayer Radioimmunotherapy Product and Solutions
Table 8. Bayer Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Bayer Recent Developments and Future Plans
Table 10. Novartis Company Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Radioimmunotherapy Product and Solutions
Table 13. Novartis Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novartis Recent Developments and Future Plans
Table 15. Lantheus Company Information, Head Office, and Major Competitors
Table 16. Lantheus Major Business
Table 17. Lantheus Radioimmunotherapy Product and Solutions
Table 18. Lantheus Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Lantheus Recent Developments and Future Plans
Table 20. Aurobindo Pharma Company Information, Head Office, and Major Competitors
Table 21. Aurobindo Pharma Major Business
Table 22. Aurobindo Pharma Radioimmunotherapy Product and Solutions
Table 23. Aurobindo Pharma Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Aurobindo Pharma Recent Developments and Future Plans
Table 25. Mundipharma Company Information, Head Office, and Major Competitors
Table 26. Mundipharma Major Business
Table 27. Mundipharma Radioimmunotherapy Product and Solutions
Table 28. Mundipharma Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Mundipharma Recent Developments and Future Plans
Table 30. China Isotope & Radiation Company Information, Head Office, and Major Competitors
Table 31. China Isotope & Radiation Major Business
Table 32. China Isotope & Radiation Radioimmunotherapy Product and Solutions
Table 33. China Isotope & Radiation Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. China Isotope & Radiation Recent Developments and Future Plans
Table 35. Curium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 36. Curium Pharmaceuticals Major Business
Table 37. Curium Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 38. Curium Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Curium Pharmaceuticals Recent Developments and Future Plans
Table 40. Gilead Sciences Company Information, Head Office, and Major Competitors
Table 41. Gilead Sciences Major Business
Table 42. Gilead Sciences Radioimmunotherapy Product and Solutions
Table 43. Gilead Sciences Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Gilead Sciences Recent Developments and Future Plans
Table 45. Clarity Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 46. Clarity Pharmaceuticals Major Business
Table 47. Clarity Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 48. Clarity Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Clarity Pharmaceuticals Recent Developments and Future Plans
Table 50. Curasight Company Information, Head Office, and Major Competitors
Table 51. Curasight Major Business
Table 52. Curasight Radioimmunotherapy Product and Solutions
Table 53. Curasight Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Curasight Recent Developments and Future Plans
Table 55. Nordic Nanovector Company Information, Head Office, and Major Competitors
Table 56. Nordic Nanovector Major Business
Table 57. Nordic Nanovector Radioimmunotherapy Product and Solutions
Table 58. Nordic Nanovector Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 59. Nordic Nanovector Recent Developments and Future Plans
Table 60. Philogen Company Information, Head Office, and Major Competitors
Table 61. Philogen Major Business
Table 62. Philogen Radioimmunotherapy Product and Solutions
Table 63. Philogen Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 64. Philogen Recent Developments and Future Plans
Table 65. RadioMedix Company Information, Head Office, and Major Competitors
Table 66. RadioMedix Major Business
Table 67. RadioMedix Radioimmunotherapy Product and Solutions
Table 68. RadioMedix Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 69. RadioMedix Recent Developments and Future Plans
Table 70. Telix Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 71. Telix Pharmaceuticals Major Business
Table 72. Telix Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 73. Telix Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 74. Telix Pharmaceuticals Recent Developments and Future Plans
Table 75. Orano Med Company Information, Head Office, and Major Competitors
Table 76. Orano Med Major Business
Table 77. Orano Med Radioimmunotherapy Product and Solutions
Table 78. Orano Med Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 79. Orano Med Recent Developments and Future Plans
Table 80. Actinium Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 81. Actinium Pharmaceuticals Major Business
Table 82. Actinium Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 83. Actinium Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 84. Actinium Pharmaceuticals Recent Developments and Future Plans
Table 85. Y-mAbs Therapeutics Company Information, Head Office, and Major Competitors
Table 86. Y-mAbs Therapeutics Major Business
Table 87. Y-mAbs Therapeutics Radioimmunotherapy Product and Solutions
Table 88. Y-mAbs Therapeutics Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Y-mAbs Therapeutics Recent Developments and Future Plans
Table 90. Fusion Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 91. Fusion Pharmaceuticals Major Business
Table 92. Fusion Pharmaceuticals Radioimmunotherapy Product and Solutions
Table 93. Fusion Pharmaceuticals Radioimmunotherapy Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Fusion Pharmaceuticals Recent Developments and Future Plans
Table 95. Global Radioimmunotherapy Revenue (USD Million) by Players (2018-2023)
Table 96. Global Radioimmunotherapy Revenue Share by Players (2018-2023)
Table 97. Breakdown of Radioimmunotherapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 98. Market Position of Players in Radioimmunotherapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 99. Head Office of Key Radioimmunotherapy Players
Table 100. Radioimmunotherapy Market: Company Product Type Footprint
Table 101. Radioimmunotherapy Market: Company Product Application Footprint
Table 102. Radioimmunotherapy New Market Entrants and Barriers to Market Entry
Table 103. Radioimmunotherapy Mergers, Acquisition, Agreements, and Collaborations
Table 104. Global Radioimmunotherapy Consumption Value (USD Million) by Type (2018-2023)
Table 105. Global Radioimmunotherapy Consumption Value Share by Type (2018-2023)
Table 106. Global Radioimmunotherapy Consumption Value Forecast by Type (2024-2029)
Table 107. Global Radioimmunotherapy Consumption Value by Application (2018-2023)
Table 108. Global Radioimmunotherapy Consumption Value Forecast by Application (2024-2029)
Table 109. North America Radioimmunotherapy Consumption Value by Type (2018-2023) & (USD Million)
Table 110. North America Radioimmunotherapy Consumption Value by Type (2024-2029) & (USD Million)
Table 111. North America Radioimmunotherapy Consumption Value by Application (2018-2023) & (USD Million)
Table 112. North America Radioimmunotherapy Consumption Value by Application (2024-2029) & (USD Million)
Table 113. North America Radioimmunotherapy Consumption Value by Country (2018-2023) & (USD Million)
Table 114. North America Radioimmunotherapy Consumption Value by Country (2024-2029) & (USD Million)
Table 115. Europe Radioimmunotherapy Consumption Value by Type (2018-2023) & (USD Million)
Table 116. Europe Radioimmunotherapy Consumption Value by Type (2024-2029) & (USD Million)
Table 117. Europe Radioimmunotherapy Consumption Value by Application (2018-2023) & (USD Million)
Table 118. Europe Radioimmunotherapy Consumption Value by Application (2024-2029) & (USD Million)
Table 119. Europe Radioimmunotherapy Consumption Value by Country (2018-2023) & (USD Million)
Table 120. Europe Radioimmunotherapy Consumption Value by Country (2024-2029) & (USD Million)
Table 121. Asia-Pacific Radioimmunotherapy Consumption Value by Type (2018-2023) & (USD Million)
Table 122. Asia-Pacific Radioimmunotherapy Consumption Value by Type (2024-2029) & (USD Million)
Table 123. Asia-Pacific Radioimmunotherapy Consumption Value by Application (2018-2023) & (USD Million)
Table 124. Asia-Pacific Radioimmunotherapy Consumption Value by Application (2024-2029) & (USD Million)
Table 125. Asia-Pacific Radioimmunotherapy Consumption Value by Region (2018-2023) & (USD Million)
Table 126. Asia-Pacific Radioimmunotherapy Consumption Value by Region (2024-2029) & (USD Million)
Table 127. South America Radioimmunotherapy Consumption Value by Type (2018-2023) & (USD Million)
Table 128. South America Radioimmunotherapy Consumption Value by Type (2024-2029) & (USD Million)
Table 129. South America Radioimmunotherapy Consumption Value by Application (2018-2023) & (USD Million)
Table 130. South America Radioimmunotherapy Consumption Value by Application (2024-2029) & (USD Million)
Table 131. South America Radioimmunotherapy Consumption Value by Country (2018-2023) & (USD Million)
Table 132. South America Radioimmunotherapy Consumption Value by Country (2024-2029) & (USD Million)
Table 133. Middle East & Africa Radioimmunotherapy Consumption Value by Type (2018-2023) & (USD Million)
Table 134. Middle East & Africa Radioimmunotherapy Consumption Value by Type (2024-2029) & (USD Million)
Table 135. Middle East & Africa Radioimmunotherapy Consumption Value by Application (2018-2023) & (USD Million)
Table 136. Middle East & Africa Radioimmunotherapy Consumption Value by Application (2024-2029) & (USD Million)
Table 137. Middle East & Africa Radioimmunotherapy Consumption Value by Country (2018-2023) & (USD Million)
Table 138. Middle East & Africa Radioimmunotherapy Consumption Value by Country (2024-2029) & (USD Million)
Table 139. Radioimmunotherapy Raw Material
Table 140. Key Suppliers of Radioimmunotherapy Raw Materials
List of Figures
Figure 1. Radioimmunotherapy Picture
Figure 2. Global Radioimmunotherapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Radioimmunotherapy Consumption Value Market Share by Type in 2022
Figure 4. Beta-emitting
Figure 5. Targeted Alpha Therapy
Figure 6. Global Radioimmunotherapy Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 7. Radioimmunotherapy Consumption Value Market Share by Application in 2022
Figure 8. Solid Tumor Picture
Figure 9. Non Hodgkin Lymphoma Picture
Figure 10. Global Radioimmunotherapy Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 11. Global Radioimmunotherapy Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 12. Global Market Radioimmunotherapy Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 13. Global Radioimmunotherapy Consumption Value Market Share by Region (2018-2029)
Figure 14. Global Radioimmunotherapy Consumption Value Market Share by Region in 2022
Figure 15. North America Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 16. Europe Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 17. Asia-Pacific Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 18. South America Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 19. Middle East and Africa Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 20. Global Radioimmunotherapy Revenue Share by Players in 2022
Figure 21. Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 22. Global Top 3 Players Radioimmunotherapy Market Share in 2022
Figure 23. Global Top 6 Players Radioimmunotherapy Market Share in 2022
Figure 24. Global Radioimmunotherapy Consumption Value Share by Type (2018-2023)
Figure 25. Global Radioimmunotherapy Market Share Forecast by Type (2024-2029)
Figure 26. Global Radioimmunotherapy Consumption Value Share by Application (2018-2023)
Figure 27. Global Radioimmunotherapy Market Share Forecast by Application (2024-2029)
Figure 28. North America Radioimmunotherapy Consumption Value Market Share by Type (2018-2029)
Figure 29. North America Radioimmunotherapy Consumption Value Market Share by Application (2018-2029)
Figure 30. North America Radioimmunotherapy Consumption Value Market Share by Country (2018-2029)
Figure 31. United States Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 32. Canada Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 33. Mexico Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 34. Europe Radioimmunotherapy Consumption Value Market Share by Type (2018-2029)
Figure 35. Europe Radioimmunotherapy Consumption Value Market Share by Application (2018-2029)
Figure 36. Europe Radioimmunotherapy Consumption Value Market Share by Country (2018-2029)
Figure 37. Germany Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 38. France Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 39. United Kingdom Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 40. Russia Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 41. Italy Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 42. Asia-Pacific Radioimmunotherapy Consumption Value Market Share by Type (2018-2029)
Figure 43. Asia-Pacific Radioimmunotherapy Consumption Value Market Share by Application (2018-2029)
Figure 44. Asia-Pacific Radioimmunotherapy Consumption Value Market Share by Region (2018-2029)
Figure 45. China Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 46. Japan Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 47. South Korea Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 48. India Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 49. Southeast Asia Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 50. Australia Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 51. South America Radioimmunotherapy Consumption Value Market Share by Type (2018-2029)
Figure 52. South America Radioimmunotherapy Consumption Value Market Share by Application (2018-2029)
Figure 53. South America Radioimmunotherapy Consumption Value Market Share by Country (2018-2029)
Figure 54. Brazil Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 55. Argentina Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 56. Middle East and Africa Radioimmunotherapy Consumption Value Market Share by Type (2018-2029)
Figure 57. Middle East and Africa Radioimmunotherapy Consumption Value Market Share by Application (2018-2029)
Figure 58. Middle East and Africa Radioimmunotherapy Consumption Value Market Share by Country (2018-2029)
Figure 59. Turkey Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 60. Saudi Arabia Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 61. UAE Radioimmunotherapy Consumption Value (2018-2029) & (USD Million)
Figure 62. Radioimmunotherapy Market Drivers
Figure 63. Radioimmunotherapy Market Restraints
Figure 64. Radioimmunotherapy Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of Radioimmunotherapy in 2022
Figure 67. Manufacturing Process Analysis of Radioimmunotherapy
Figure 68. Radioimmunotherapy Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
